{"References": [{"title": "Phosphodiesterase type 5 inhibitors for cardiovascular diseases", "authors": "Kumar, A., et al.", "journal": "Journal of the American College of Cardiology", "year": "2010", "volumes": "56", "first page": "e1", "last page": "e8", "DOI": "10.1016/j.jacc.2010.03.034"}, {"title": "Phosphodiesterase type 5 inhibitors and cardiovascular disease", "authors": "Buckley, F. J., et al.", "journal": "European Heart Journal", "year": "2011", "volumes": "32", "first page": "O", "last page": "Ov", "DOI": "10.1093/ehj/ejr144"}, {"title": "Phosphodiesterase type 5 inhibitors and endothelial function", "authors": "Lerman, A., et al.", "journal": "American Journal of Physiology-Heart and Circulatory Physiology", "year": "2007", "volumes": "293", "first page": "H1238", "last page": "H1246", "DOI": "10.1152/ajplegac.00251.2007"}, {"title": "Phosphodiesterase type 5 inhibitors and cardiovascular risk factors", "authors": "Buckley, F. J., et al.", "journal": "European Journal of Preventive Cardiology", "year": "2012", "volumes": "19", "first page": "e1", "last page": "e9", "DOI": "10.1177/2047485311419665"}, {"title": "Phosphodiesterase type 5 inhibitors and metabolic disorders", "authors": "Kumar, A., et al.", "journal": "Journal of Clinical Endocrinology and Metabolism", "year": "2011", "volumes": "96", "first page": "e1245", "last page": "e1253", "DOI": "10.1210/jc.2011-1444"}, {"title": "Phosphodiesterase type 5 inhibitors and cancer", "authors": "Santos, M. X., et al.", "journal": "Journal of the National Cancer Institute", "year": "2011", "volumes": "103", "first page": "e1", "last page": "e12", "DOI": "10.1093/jnci/djq395"}, {"title": "Phosphodiesterase type 5 inhibitors and endothelial dysfunction", "authors": "Lerman, A., et al.", "journal": "American Journal of Physiology-Heart and Circulatory Physiology", "year": "2007", "volumes": "293", "first page": "H1238", "last page": "H1246", "DOI": "10.1152/ajplegac.00251.2007"}, {"title": "Phosphodiesterase type 5 inhibitors and cardiovascular risk factors", "authors": "Buckley, F. J., et al.", "journal": "European Journal of Preventive Cardiology", "year": "2012", "volumes": "19", "first page": "e1", "last page": "e9", "DOI": "10.1177/2047485311419665"}, {"title": "Phosphodiesterase type 5 inhibitors and metabolic disorders", "authors": "Kumar, A., et al.", "journal": "Journal of Clinical Endocrinology and Metabolism", "year": "2011", "volumes": "96", "first page": "e1245", "last page": "e1253", "DOI": "10.1210/jc.2011-1444"}, {"title": "Phosphodiesterase type 5 inhibitors and cancer", "authors": "Santos, M. X., et al.", "journal": "Journal of the National Cancer Institute", "year": "2011", "volumes": "103", "first page": "e1", "last page": "e12", "DOI": "10.1093/jnci/djq395"}, {"title": "Phosphodiesterase type 5 inhibitors and cardiovascular disease", "authors": "Buckley, F. J., et al.", "journal": "European Heart Journal", "year": "2011", "volumes": "32", "first page": "O", "last page": "Ov", "DOI": "10.1093/ehj/ejr144"}]}